Skip to main content
. 2022 Aug 25;36(10):2351–2367. doi: 10.1038/s41375-022-01666-2

Fig. 6. High-throughput screening for novel drugs in NPM1-mutated AML.

Fig. 6

A Workflow of microscopy-based screening strategy (created with BioRender.com). B Example of 96 well plate subjected to image and data processing (generated with ShinyHTM software). Arrows indicate results obtained with XPO1 inhibitors (KPT-185, KPT-276 and KPT-330). The higher number of points for selinexor (KPT-330) results from its use as a positive control.